^
Association details:
Biomarker:MYC overexpression
Cancer:Acute Myelogenous Leukemia
Drug:WB100 (MYC inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors

Published date:
01/20/2022
Excerpt:
To assess in vivo the effect of WBC100 on c-Myc overexpressing cancer cells of hematological malignancies, we next established an orthotopic human AML model…At a low dose (0.1 mg kg–1), WBC100 also significantly inhibited tumor growth and prolonged survival of leukemia mice...WBC100 potently regresses c-Myc overexpressing AML in vivo...
DOI:
https://doi.org/10.1002/advs.202104344